Potent ALK inhibitor (IC50
values are 1.3, 2.4, 85.8, 2,133 and 9,276 nM for ALK2, ALK1, ALK3, ALK4 and ALK5, respectively). Exhibits selectivity for ALK2 over ALK4 and ALK5 in cellular assays. Inhibits heterotopic ossification in a mutant ALK2 mouse model of fibrodysplasia ossificans progressiva. Also exhibits activity against RIPK2, ABL1 and PDGFR-β (IC50
values < 100 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patent 14/776,302
Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas et al.
ACS Chem.Biol., 2013;8:1291